November 02, 2017
Sponsored by

Validation of a UMI-Powered NGS Panel for Improved Variant Calling


Director, Labsolutions, LLC

Global Product Manager, Qiagen

This webinar discusses the benefits of using unique molecular indices to overcome some challenges associated with next-generation sequencing panels.

Targeted NGS panels have been instrumental in advancing the field of cancer genomics by enabling the analysis of hundreds of mutations across many genes in an individual assay.

The biggest challenges, however, to realizing the full benefits of targeted NGS panels are 1) PCR duplicates and errors introduced during the workflow, which result in reduced confidence in calling variants such as single nucleotide variants and indels; 2) low levels of enrichment and sequencing uniformity, which affect the ability to call low-frequency variants; and 3) long turnaround times and high DNA input requirements, which limit the practicality of NGS panels.

These challenges can be overcome by building a robust workflow with short turnaround times that incorporates unique molecular indices (UMIs) to correct for PCR errors and single primer extension (SPE) to enhance uniformity and reduce the DNA input requirements.

During this webinar, Dr. Bernadette Wildemore of Labsolutions discusses the validation of a UMI-powered DNA panel and associated bioinformatics pipelines in high-throughput routine use. Dr. Raed Samara of Qiagen then discusses the benefits of incorporating UMIs and SPE to overcome the current challenges of using targeted NGS panels.

Sponsored by

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.

Sponsored by

 This webinar will share details from a study at the Saint-Antoine Research Center, Sorbonne University to test the feasibility of a high-sensitivity, clone-specific strategy for evaluating minimal residual disease (MRD) in acute myeloid leukemia (AML). 

Sponsored by
Thermo Fisher Scientific

In this webinar, the second in the “New Frontiers in Liquid Biopsy Research” series, Luca Quagliata, Senior Consultant in the Molecular Pathology Unit at University Hospital Basel, will share two specific unmet needs within his lab’s liquid biopsy research that led to the eventual evaluation, adoption, and implementation of the latest liquid biopsy Oncomine NGS solutions from Thermo Fisher.

Sponsored by
Horizon Discovery

This webinar will provide an in-depth case study demonstrating how reference standards can be used to develop and validate circulating tumor DNA (ctDNA)-based assays.

Sponsored by
Canon BioMedical

This webinar will introduce new technologies that enable multidimensional measurements from single cells to obtain a more complete picture of a cell’s phenotype and gene expression.